TAK-733 Chemical Properties

Boiling point:

530.5±60.0 °C(Predicted)

Density 

1.91±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

≥25.2 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O

form 

solid

pka

13.72±0.20(Predicted)

color 

White to light yellow

Safety Information

HS Code 

2933399990

TAK-733 Usage And Synthesis

Description

TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc. Phase 1.

In vitro

TAK-733 is highly potent and selective MEK allosteric site inhibitor with IC50 of 3.2 nM. TAK-733 shows potent enzymatic and cell activity with an EC50 of 1.9 nM against ERK phosphorylation in cells.

In vivo

TAK-733 demonstrates broad antitumor activity in mouse xenograft models of human cancer including models of melanoma, colorectal, NSCLC, pancreatic and breast cancer. TAK-733 is well tolerated with pharmacokinetics and pharmacodynamics that support once-daily oral dosing in humans. TAK-733 shows maximally efficacious doses at once daily orally doses of 10 mg/kg.

Uses

TAK-733 is a potent and selective MEK allosteric site inhibitor with an IC50 of 3.2 nM.

Biological Activity

tak-733 is a potent, atp-noncompetitive and selective inhibitor of mek allosteric site with the ic50 value of 3.2nm [1].tak-733 has been shown potent enzymatic and cell activity with an ic50 value of 3.2nm against constitutively active mek enzyme and an ec50 of 1.9nm against erk phosphorylation in cells. in addition, tak-733 has also shown the low clearance and high oral bioavailability based on the pharmacokinetics of tak-733 in all species (mouse, rat, dog and monkey). furthermore, tak-733 has been reported to broad inhibit tumor activity in mouse xenograft models of human cancer (melanoma, colorectal, nsclc, pancreatic and breast cancer) [1].

Synthesis

Example 18: (i) To a solution of 3-(2,3-dihydroxypropyl)-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidin-4,7(3H,8H)-dione (Example 6) (1 g, 2.06 mmol, 1 eq.) in DMF (19 mL) was added dropwise under nitrogen protection at ambient temperature a solution of Selectfluor (801 mg, 2.26 mmol, 1.1 eq.) in a mixture of acetonitrile (9 mL) and DMF (5 mL). The reaction mixture was stirred at ambient temperature for 10 minutes and then filtered. The filtrate was purified by preparative LC/MS (30-55% CH3CN/H2O) to afford (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (Example 18) as an off-white solid. The recovered feedstock was reacted under the same reaction conditions to give a second batch of product. The total yield was 347 mg (33%).1H NMR (400 MHz, DMSO-J6) δ ppm 3.36-3.40 (m, 1H), 3.43-3.50 (m, 1H), 3.58 (s, 3H), 3.61-3.72 (m, 1H), 3.72-3.82 (m, 1H), 4.27-4.37 (m, 1H) , 4.78-4.87 (m, 1H), 5.14 (d, J = 5.81 Hz, 1H), 6.93-7.03 (m, 1H), 7.53 (d, J = 8.84 Hz, 1H), 7.65-7.74 (m, 1H), 8.52 (s, 1H), 10.25 (d, J = 10.1 Hz, 1H). The calculated value for [M + H] C17H15F2IN4O4 is 505; the measured value is 505.

in vivo

target

MEK1

IC 50

MEK: 3.2 nM (IC₅₀)

References

[1] dong q1, dougan dr, gong x, halkowycz p, jin b, kanouni t, o'connell sm, scorah n, shi l, wallace mb, zhou f. discovery of tak-733, a potent and selective mek allosteric site inhibitor for the treatment of cancer. bioorg med chem lett. 2011 mar 1;21(5):1315-9. doi: 10.1016/j.bmcl.2011.01.071. epub 2011 jan 22.

TAK-733(1035555-63-5)Related Product Information

• 6-[(7S)-7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methyl-2-naphthalenecarboxamide
• ARRY-424704, ARRY-704
• Selumetinib
• Tipifarnib
• Trametinib
• PLX4032
• Fedratinib
• RESATORVID
• TAK-063
• Vonoprazan fumarate
• INK1117
• Mobocertinib
• Tak 799
• TAK-960
• Soticlestat
• TAK-632
• TAK875
• Benzoic acid, 4-[[(cyclopropylmethyl)[4-(2-fluorophenoxy)benzoyl]amino]methyl]-